Biopharmaceutical company focused on the discovery, development and commercialization of patient-friendly medicinal therapies; its lead candidate is ivonescimab, a bispecific antibody for non-small cell lung cancer and colorectal cancer. Originally a UK plc, the group reorganized into a US entity and is now headquartered in Miami, Florida.
相关临床试验
15
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2003
进行中（未招募）
2
13.3%
已完成
5
33.3%
招募中
6
40.0%
终止
2
13.3%
暂无批准数据
- Updated Phase III HARMONi results presented at WCLC 2026 show ivonescimab plus chemotherapy achieved an overall survival hazard ratio of 0.76 in EGFR-mutated NSCLC. - With median follow-up extended to 23.2 months, western patients replicated the survival improvement previously seen in Asian patients, supporting regional consistency. - The Akeso-sponsored HARMONi-2 study reported ivonescimab monotherapy beat pembrolizumab on overall survival with a hazard ratio of 0.73 in PD-L1-positive NSCLC. - Summit's Biologics License Application for ivonescimab in this indication has an FDA PDUFA goal action date of November 14, 2026.
- Akeso's Phase III HARMONi-2 trial met its overall survival endpoint, with ivonescimab monotherapy cutting the risk of death by 27% versus pembrolizumab in first-line PD-L1-positive advanced NSCLC. - Median overall survival reached 30.8 months with ivonescimab versus 22.6 months with pembrolizumab (HR=0.73; 95% CI 0.57-0.95; P=0.009) at 36 months of median follow-up. - Benefit was most pronounced in PD-L1-high patients (TPS >=50%), where the hazard ratio was 0.58, corresponding to a 42% reduction in the risk of death. - No apparent increase in bleeding risk was observed among high-risk squamous patients, a population traditionally considered contraindicated for anti-VEGF therapy.
- Summit Therapeutics has signed an agreement to sell its Phase III precision antibiotic ridinilazole to Toronto-based Biossil, Inc., an AI-native biopharma company focused on life-threatening indications with urgent unmet needs. - Ridinilazole previously demonstrated a higher observed Sustained Clinical Response rate than vancomycin in the Phase III Ri-CoDIFy study for C. difficile infection but did not meet the primary endpoint for superiority. - Summit will receive $500,000 upfront and up to $104.5 million in regulatory and commercial milestones, plus tiered royalties on net sales, while refocusing on its core oncology strategy. - C. difficile causes nearly 500,000 infections and contributes to more than 29,000 deaths annually in the United States, underscoring the urgent need for novel microbiome-sparing antibiotics.
- The global EGFR inhibitors market reached USD 7 billion in 2025 across the 7MM, with the United States accounting for approximately 60% of total market share. - A wave of emerging therapies including zipalertinib, firmonertinib, ivonescimab, and multiple ADC candidates is expected to reshape the treatment landscape for EGFR-mutated cancers. - The FDA has set PDUFA action dates for ivonescimab (November 14, 2026) and zipalertinib (February 27, 2027), signaling imminent regulatory decisions for two novel agents. - EGFR exon 20 insertion mutations have emerged as a key competitive arena, with approvals of amivantamab and sunvozertinib creating a distinct market segment.
- Mizuho healthcare strategist Jared Holz argues that years of underperformance have repositioned healthcare as a value sector, offering a counterbalance for growth-heavy portfolios concentrated in AI and technology stocks. - The Nasdaq-100 surged 63.91% over two years while Merck stock declined 4.32%, illustrating the stark performance gap driving the sector's value proposition. - Merck's Keytruda franchise generated $8.03 billion in Q1 2026 sales, up 12%, with Holz emphasizing that competitors are forced into partnership rather than head-on competition due to Keytruda's dominance as a backbone therapy. - Summit Therapeutics' ivonescimab, a bispecific PD-1/VEGF antibody, faces a binary-risk FDA PDUFA decision on November 14, 2026 for EGFR-mutated NSCLC, with questions remaining about the translatability of China-conducted trial data to Western populations.
- Summit Therapeutics abruptly withdrew a $500 million secondary share offering one day after announcing it, citing "market conditions." - The cancellation follows mixed data for ivonescimab, a PD-1/VEGF bispecific antibody, including a missed interim statistical significance mark in the global HARMONi-3 Phase 3 trial. - Summit held nearly $600 million in cash as of March 31 but faces high R&D spending, with analysts projecting a cash runway potentially extending only to 2027. - The ivonescimab program remains in a global Phase 3 trial intended to support FDA approval, though investor and physician debate over its efficacy continues.
- Avacta Therapeutics has appointed Francis Wilson as Chief Scientific Officer, promoting him from Vice President of Chemistry after demonstrating expertise in developing the company's pre|CISION tumor-activated oncology delivery platform. - Wilson has been instrumental in developing novel intellectual property around the pre|CISION mechanism, particularly the sustained release mechanism that forms the backbone of the FAP-Exd (AVA6103) program anticipated to begin clinical testing soon. - The leadership change comes as former CSO Michelle Morrow departs to pursue other opportunities, with Wilson bringing over 30 years of medicinal chemistry experience from companies including Roche, Summit Therapeutics, and Cellzome. - Wilson's appointment positions Avacta for a period of significant preclinical development and intellectual property generation as the company advances its tumor-specific protease-based drug delivery platform.
- Summit Therapeutics has submitted a Biologics License Application to the FDA for ivonescimab, a first-in-class bispecific antibody, in combination with chemotherapy for previously treated EGFR-mutated non-squamous non-small cell lung cancer. - The BLA submission is supported by Phase III HARMONi trial data, with the pivotal global Phase III HARMONi-3 lung cancer study expected to report results in 2026. - Cantor Fitzgerald reiterated its Overweight rating while Barclays upgraded Summit to Equalweight, highlighting the late-2025 BLA filing and 2026 HARMONi-3 readout as major inflection points. - The company is expanding its clinical footprint into colorectal and other solid tumors, positioning ivonescimab as the foundation for a multi-indication oncology franchise.
- China has accelerated drug development timelines by 50-70% through parallelized workflows and dense CRO ecosystems, capturing 39% of global clinical research share in 2023. - Major pharmaceutical companies are increasingly licensing Chinese assets not just for promising drugs, but to learn operational efficiency strategies that could transform their R&D processes. - While the FDA requires 20% of testing in the U.S. for drug approval, the remaining 80% can be conducted globally, creating opportunities for regions like China, Australia, and South Korea to attract clinical trials. - Chinese licensing deals have surged from 8% to 30% of global licensing activity in just two years, reflecting growing East-West collaboration in drug development.
- Summit Therapeutics' ivonescimab demonstrated significantly better outcomes in Asian patients compared to Western populations in the Phase III HARMONi trial for EGFR-mutant non-small cell lung cancer. - The drug achieved a 45% reduction in tumor progression risk in Chinese patients but only a 33% reduction in Western patients, failing to reach statistical significance in the latter group. - Overall survival benefits varied by region, with a 24% improvement in Asian patients versus 16% in Western patients, raising questions about FDA approval prospects. - The FDA has indicated that statistically significant overall survival benefit is necessary for U.S. marketing authorization, creating regulatory uncertainty for the drug's approval path.
